Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-05 03:31 | 2026-03-02 | ALNY | Alnylam Pharmaceuticals Inc. | Poulton Jeffrey V. | Officer | SELL | $327.65 | 2,206 | $722,801 | 64,273 |
| 2026-03-05 03:42 | 2026-03-03 | XNCR | Xencor Inc | Dahiyat Bassil I | Director, Officer | SELL | $11.90 | 6,758 | $80,387 | 567,792 |
| 2026-03-05 03:42 | 2026-03-03 | XNCR | Xencor Inc | Eckert Celia | Officer | SELL | $11.90 | 1,492 | $17,747 | 81,929 |
| 2026-03-05 03:43 | 2026-03-03 | XNCR | Xencor Inc | Desjarlais John R | Officer | SELL | $11.90 | 2,663 | $31,677 | 270,451 |
| 2026-03-05 03:29 | 2026-03-02 | ALNY | Alnylam Pharmaceuticals Inc. | Greenstreet Yvonne | Director, Officer | SELL | $327.65 | 6,799 | $2,227,698 | 98,628 |
| 2026-03-05 03:00 | 2026-03-02 | SEPN | Septerna, Inc. | Shaikhly Samira | Officer | OPT+S | $28.10 | 70,453 | $1,979,835 | 793 |
| 2026-03-05 02:45 | 2026-03-03 | ANIP | Ani Pharmaceuticals Inc. | Gutwerg Ori | Officer | SELL | $76.50 | 2,060 | $157,590 | 84,782 |
| 2026-03-05 02:46 | 2026-03-02 | ANIP | Ani Pharmaceuticals Inc. | Mutz Christopher | Officer | SELL | $74.00 | 417 | $30,858 | 103,508 |
| 2026-03-05 02:51 | 2026-03-02 | VNDA | Vanda Pharmaceuticals Inc. | Birznieks Gunther | Officer | SELL | $8.27 | 42,431 | $350,730 | 494,197 |
| 2026-03-05 02:51 | 2026-03-02 | VNDA | Vanda Pharmaceuticals Inc. | Polymeropoulos Mihael Hristos | Director, Officer | SELL | $8.17 | 156,235 | $1,276,971 | 2,704,496 |
| 2026-03-05 02:52 | 2026-03-02 | VNDA | Vanda Pharmaceuticals Inc. | Wijkstrom Joakim | Officer | SELL | $8.27 | 30,800 | $254,590 | 333,469 |
| 2026-03-05 02:53 | 2026-03-02 | VNDA | Vanda Pharmaceuticals Inc. | Moran Kevin Patrick | Officer | SELL | $8.27 | 42,442 | $350,821 | 411,380 |
| 2026-03-05 02:54 | 2026-03-02 | VNDA | Vanda Pharmaceuticals Inc. | Williams Timothy | Officer | SELL | $8.27 | 42,434 | $350,755 | 377,450 |
| 2026-03-05 02:08 | 2026-03-02 | PMN | ProMIS Neurosciences Inc. | Williams Eugene | Director | BUY | $23.11 | 4,000 | $92,420 | 10,397 |
| 2026-03-05 01:50 | 2026-03-02 | FBLG | FibroBiologics, Inc. | O'HEERON PETE | Director, Officer | BUY | $0.38 | 51,500 | $19,529 | 5,958,147 |
| 2026-03-05 01:43 | 2026-03-03 | CRNX | Crinetics Pharmaceuticals, Inc. | Schilke Tobin | Officer | SELL | $39.67 | 6,713 | $266,305 | 78,121 |
| 2026-03-05 01:44 | 2026-03-03 | CRNX | Crinetics Pharmaceuticals, Inc. | Okey Stephanie | Director | SELL | $39.67 | 3,000 | $119,010 | 13,300 |
| 2026-03-05 01:28 | 2026-03-02 | XERS | Xeris Biopharma Holdings, Inc. | Hecht Beth | Officer | SELL | $6.25 | 16,667 | $104,085 | 1,226,507 |
| 2026-03-05 01:11 | 2026-03-02 | RPRX | Royalty Pharma plc | Coyne Terrance P. | Officer | SELL | $46.78 | 34,791 | $1,627,533 | 45,761 |
| 2026-03-05 00:55 | 2026-03-02 | IRON | Disc Medicine, Inc. | Savage William Jacob | Officer | SELL | $65.88 | 7,378 | $486,069 | 85,211 |
| 2026-03-05 00:40 | 2026-03-02 | KNSA | Kiniksa Pharmaceuticals International, plc | Paolini John F. | Officer | OPT+S | $44.82 | 40,000 | $1,792,940 | 61,324 |
| 2026-03-05 00:42 | 2026-03-02 | QURE | uniQure N.V. | Kapusta Matthew C | Director, Officer | SELL | $9.95 | 34,437 | $342,648 | 604,639 |
| 2026-03-05 00:24 | 2026-03-03 | JAZZ | Jazz Pharmaceuticals plc | COZADD BRUCE C | Director | SELL | $186.44 | 6,000 | $1,118,614 | 405,796 |
| 2026-03-05 00:25 | 2026-03-02 | QURE | uniQure N.V. | Abi-Saab Walid | Officer | SELL | $9.95 | 1,660 | $16,517 | 148,777 |
| 2026-03-05 00:28 | 2026-03-02 | STOK | Stoke Therapeutics, Inc. | Krainer Adrian R. | Director | SELL | $39.66 | 7,229 | $286,715 | 316,545 |
| 2026-03-04 01:43 | 2026-03-02 | BHC | Bausch Health Companies Inc. | Carson Seana | Officer | SELL | $5.78 | 11,276 | $65,131 | 616,761 |
| 2026-03-04 00:34 | 2026-03-02 | LQDA | Liquidia Corp | Schundler Russell | Officer | OPT+S | $30.58 | 1,073 | $32,812 | 614,057 |
| 2026-03-04 00:33 | 2026-03-02 | LQDA | Liquidia Corp | Moomaw Scott | Officer | OPT+S | $30.58 | 827 | $25,290 | 188,954 |
| 2026-03-04 00:32 | 2026-03-02 | LQDA | Liquidia Corp | Krepp Sarah | Officer | SELL | $30.58 | 276 | $8,440 | 164,658 |
| 2026-03-04 00:30 | 2026-03-02 | LQDA | Liquidia Corp | Boyle Dana | Officer | SELL | $30.58 | 445 | $13,608 | 178,840 |
| 2026-03-04 00:21 | 2026-02-27 | JNJ | JOHNSON & JOHNSON | Decker Robert J | Officer | OPT+S | $247.87 | 4,075 | $1,010,070 | 23,682 |
| 2026-03-04 04:00 | 2026-03-02 | ABT | Abbott Laboratories | Moreland Mary K | Officer | SELL | $115.58 | 613 | $70,851 | 104,291 |
| 2026-03-04 00:30 | 2026-03-02 | LQDA | Liquidia Corp | Adair Jason | Officer | OPT+S | $30.58 | 689 | $21,070 | 212,479 |
| 2026-03-04 00:17 | 2026-02-27 | BBIO | BridgeBio Pharma, Inc. | Valantine Hannah | Director | OPT+S | $67.41 | 25,484 | $1,717,780 | 7,465 |
| 2026-03-04 00:34 | 2026-02-27 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Kewalramani Reshma | Director, Officer | SELL | $493.47 | 40,000 | $19,738,856 | 98,278 |
| 2026-03-04 00:31 | 2026-03-02 | LQDA | Liquidia Corp | Kaseta Michael | Officer | OPT+S | $30.58 | 1,165 | $35,626 | 411,855 |
| 2026-03-04 01:00 | 2026-03-02 | EDSA | Edesa Biotech, Inc. | Nijhawan Pardeep | Director, Officer, 10% owner | BUY | $2.09 | 3,000 | $6,280 | 372,702 |
| 2026-03-04 02:51 | 2026-03-02 | RARE | Ultragenyx Pharmaceutical Inc. | Parschauer Karah Herdman | Officer | SELL | $22.80 | 8,135 | $185,478 | 76,346 |
| 2026-03-04 02:51 | 2026-03-02 | RARE | Ultragenyx Pharmaceutical Inc. | Huizenga Theodore Alan | Officer | SELL | $22.80 | 1,632 | $37,210 | 48,670 |
| 2026-03-04 02:50 | 2026-03-02 | RARE | Ultragenyx Pharmaceutical Inc. | Horn Howard | Officer | SELL | $22.65 | 10,044 | $227,538 | 85,034 |
| 2026-03-04 02:49 | 2026-03-02 | RARE | Ultragenyx Pharmaceutical Inc. | Crombez Eric | Officer | SELL | $22.80 | 7,029 | $160,261 | 76,301 |
| 2026-03-04 00:29 | 2026-03-02 | KPTI | Karyopharm Therapeutics Inc. | Abate Kristin | Officer | SELL | $9.41 | 559 | $5,260 | 22,063 |
| 2026-03-04 00:17 | 2026-03-02 | KPTI | Karyopharm Therapeutics Inc. | Poulton Stuart | Officer | SELL | $9.41 | 5,101 | $47,998 | 94,328 |
| 2026-03-04 00:27 | 2026-03-02 | KPTI | Karyopharm Therapeutics Inc. | Cheng Sohanya Roshan | Officer | SELL | $9.41 | 4,604 | $43,321 | 107,317 |
| 2026-03-04 00:28 | 2026-03-02 | KPTI | Karyopharm Therapeutics Inc. | Mano Michael | Officer | SELL | $9.41 | 3,526 | $33,178 | 93,964 |
| 2026-03-04 00:21 | 2026-03-02 | KPTI | Karyopharm Therapeutics Inc. | Paulson Richard A. | Director, Officer | SELL | $9.41 | 12,361 | $116,311 | 267,030 |
| 2026-03-04 00:34 | 2026-03-02 | SDGR | Schrodinger, Inc. | Farid Ramy | Director, Officer | SELL | $11.90 | 5,560 | $66,151 | 334,485 |
| 2026-03-04 00:31 | 2026-03-02 | SDGR | Schrodinger, Inc. | Akinsanya Karen | Officer | SELL | $11.99 | 2,206 | $26,454 | 71,322 |
| 2026-03-04 00:17 | 2026-03-02 | AGIO | Agios Pharmaceuticals Inc. | Goff Brian | Director, Officer | OPT+S | $28.96 | 18,055 | $522,873 | 164,548 |
| 2026-03-04 00:17 | 2026-03-02 | AGIO | Agios Pharmaceuticals Inc. | Burns James William | Officer | OPT+S | $28.96 | 5,218 | $151,113 | 44,086 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.